Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathrine E Attfield

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Immunological Reviews|June 26, 2012
Bridging the gap from genetic association to functional understanding: the next generation of mouse models of multiple sclerosisKathrine E Attfield, Calliope A Dendrou, Lars Fugger
Ebiomedicine|October 20, 2023
Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitorsLise Torp Jensen, Kathrine E Attfield, Marc Feldmann, et al.
Nature Reviews. Immunology|May 4, 2022
The immunology of multiple sclerosisKathrine E Attfield, Lise Torp Jensen, Max Kaufmann, et al.
European Journal of Immunology|July 22, 2014
CD8⁺ MAIT cells infiltrate into the CNS and alterations in their blood frequencies correlate with IL-18 serum levels in multiple sclerosisAnne Willing, Oliver A Leach, Friederike Ufer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 21, 2008
Invariant NKT cells promote CD8+ cytotoxic T cell responses by inducing CD70 expression on dendritic cellsVadim Y Taraban, Sonya Martin, Kathrine E Attfield, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 28, 2016
Multiple sclerosis: Molecular mimicry of an antimyelin HLA class I restricted T-cell receptorGeraldine Rühl, Anna G Niedl, Atanas Patronov, et al.
Med (New York, N.Y.)|March 22, 2021
Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosisMax Kaufmann, Hayley Evans, Anna-Lena Schaupp, et al.
Blood|June 28, 2008
Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activationStephen A Beers, Claude H T Chan, Sonya James, et al.
Nature Communications|June 27, 2017
Structural and regulatory diversity shape HLA-C protein expression levelsGurman Kaur, Stephanie Gras, Jesse I Mobbs, et al.
Cell Death & Disease|May 3, 2020
A novel neurodegenerative spectrum disorder in patients with MLKL deficiencySoren L Faergeman, Hayley Evans, Kathrine E Attfield, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Immunological Reviews|June 26, 2012
Bridging the gap from genetic association to functional understanding: the next generation of mouse models of multiple sclerosisKathrine E Attfield, Calliope A Dendrou, Lars Fugger
Ebiomedicine|October 20, 2023
Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitorsLise Torp Jensen, Kathrine E Attfield, Marc Feldmann, et al.
Nature Reviews. Immunology|May 4, 2022
The immunology of multiple sclerosisKathrine E Attfield, Lise Torp Jensen, Max Kaufmann, et al.
European Journal of Immunology|July 22, 2014
CD8⁺ MAIT cells infiltrate into the CNS and alterations in their blood frequencies correlate with IL-18 serum levels in multiple sclerosisAnne Willing, Oliver A Leach, Friederike Ufer, et al.
Journal of Immunology (Baltimore, Md. : 1950)|March 21, 2008
Invariant NKT cells promote CD8+ cytotoxic T cell responses by inducing CD70 expression on dendritic cellsVadim Y Taraban, Sonya Martin, Kathrine E Attfield, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|May 28, 2016
Multiple sclerosis: Molecular mimicry of an antimyelin HLA class I restricted T-cell receptorGeraldine Rühl, Anna G Niedl, Atanas Patronov, et al.
Med (New York, N.Y.)|March 22, 2021
Identifying CNS-colonizing T cells as potential therapeutic targets to prevent progression of multiple sclerosisMax Kaufmann, Hayley Evans, Anna-Lena Schaupp, et al.
Blood|June 28, 2008
Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activationStephen A Beers, Claude H T Chan, Sonya James, et al.
Nature Communications|June 27, 2017
Structural and regulatory diversity shape HLA-C protein expression levelsGurman Kaur, Stephanie Gras, Jesse I Mobbs, et al.
Cell Death & Disease|May 3, 2020
A novel neurodegenerative spectrum disorder in patients with MLKL deficiencySoren L Faergeman, Hayley Evans, Kathrine E Attfield, et al.
Pageof 2